Arab Drug and Chemical Industries invited shareholders to attend an ordinary general meeting scheduled for Tuesday, September 23, 2014, to look into ratifying the company’s final accounts and financial statements for the fiscal year that ended on June 30, 2014.
Board members will be discharged from liability for the same FY.
The company’s FY13/14 financial results had shown a surge by 927% in net profit to EGP 3.2 million, compared with EGP 320 thousand net profit a year earlier.
The company’s total sales reached EGP 205.9 million, compared with EGP 172.6 million in FY12/13.
The company had posted EGP 2.8 million net profit for the first nine months of FY13/14, with a surge by 353% y/y from EGP 623 thousand.
Board members will be discharged from liability for the same FY.
The company’s FY13/14 financial results had shown a surge by 927% in net profit to EGP 3.2 million, compared with EGP 320 thousand net profit a year earlier.
The company’s total sales reached EGP 205.9 million, compared with EGP 172.6 million in FY12/13.
The company had posted EGP 2.8 million net profit for the first nine months of FY13/14, with a surge by 353% y/y from EGP 623 thousand.
Source:
Mubasher
